Literature DB >> 3215287

Ontogenesis of the formation of secretory antibodies to respiratory syncytial (RS) virus.

N P Leschinskaya1, E E Pokrovskaya, E A Kantorovitch, S K Grigorjeva.   

Abstract

Examination of sera from 184 children aged between 0 and 12 years and 161 adults revealed a close correlation between age and the level of humoral anti-RS virus immunity. Secretory IgG antibodies were found in children in their first months of life. Evidence for their release into secretions from the serum was obtained. This might explain the positive correlation between serum antibody levels in women recently confined with the morbidity due to RS virus in children during their first months of life. Secretory IgA antibodies were found from 4 months until old age. The secretions of children and adults contained virus-neutralizing activity which was non-immunoglobulin in nature, as well as antibodies. However, in contrast to secretory antibody this material did not prevent development of severe RS virus infections.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3215287      PMCID: PMC2249405          DOI: 10.1017/s0950268800029435

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  25 in total

1.  Serodiagnosis of influenza by indirect haemagglutination test.

Authors:  E P Korneeva; A N Naykhin
Journal:  Acta Virol       Date:  1977-05       Impact factor: 1.162

2.  Respiratory syncytial virus neutralizing activity in nasal secretions following natural infection.

Authors:  H W Kim; J A Bellanti; J O Arrobio; J Mills; C D Brandt; R M Chanock; R H Parrott
Journal:  Proc Soc Exp Biol Med       Date:  1969-06

3.  Breast-feeding as protection against respiratory syncytial virus.

Authors:  G Evans-Jones; D W Fielding; P J Todd; M Tomlinson
Journal:  Br Med J       Date:  1978-11-18

4.  Detection of IgA antibodies by the red cell linked antigen-antiglobulin reaction: antibodies in the sera of infants to milk proteins.

Authors:  R R Coombs; W E Jonas; P J Lachmann; A Feinstein
Journal:  Int Arch Allergy Appl Immunol       Date:  1965

5.  The immunologic response to infection with respiratory syncytial virus in infants.

Authors:  K McIntosh; H B Masters; I Orr; R K Chao; R M Barkin
Journal:  J Infect Dis       Date:  1978-07       Impact factor: 5.226

6.  Respiratory syncytial virus in early infancy. Circulating antibody and the severity of infection.

Authors:  F W Bruhn; A S Yeager
Journal:  Am J Dis Child       Date:  1977-02

7.  Respiratory syncytial virus neutralizing activity in nasopharyngeal secretions.

Authors:  R Scott; P S Gardner
Journal:  J Hyg (Lond)       Date:  1970-12

8.  Nosocomial respiratory syncytial virus infections.

Authors:  C B Hall; R G Douglas; J M Geiman; M K Messner
Journal:  N Engl J Med       Date:  1975-12-25       Impact factor: 91.245

9.  An outbreak of streptococcal sore throat and rheumatic fever in a Royal Air Force training camp; significance of serum antibody to M-associated protein.

Authors:  J P Widdowson; W R Maxted; C W Newrick; D Parkin
Journal:  J Hyg (Lond)       Date:  1974-02

Review 10.  Prevention of infections with respiratory syncytial virus: the hopes and hurdles ahead.

Authors:  C B Hall
Journal:  Rev Infect Dis       Date:  1980 May-Jun
View more
  3 in total

1.  Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies.

Authors:  H B Gimenez; S Chisholm; J Dornan; P Cash
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

2.  In Vitro Enhancement of Respiratory Syncytial Virus Infection by Maternal Antibodies Does Not Explain Disease Severity in Infants.

Authors:  Elisabeth A van Erp; Puck B van Kasteren; Teun Guichelaar; Inge M L Ahout; Cornelis A M de Haan; Willem Luytjes; Gerben Ferwerda; Oliver Wicht
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

Review 3.  Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease.

Authors:  Elisabeth A van Erp; Willem Luytjes; Gerben Ferwerda; Puck B van Kasteren
Journal:  Front Immunol       Date:  2019-03-22       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.